The short version of mass spectrometry fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-11-29 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
== Genetics == Mutations in one of several genes cause the various types of Emery–Dreifuss muscular dystrophy. Mutation of the EMD or LMNA gene is the cause in 40% of cases. Each gene implicated in EDMD provides instructions for making a protein that is associated with the nuclear envelope, which surrounds the nucleus of a cell. The nuclear envelope regulates the movement of molecules into and out of the nucleus, and researchers believe it may play a role in regulating the activity of certain genes.
== Causes == The majority of reports are of random lesions, but there are some familial cases, indicating autosomal dominant transmission. Furthermore, connective tissue nevus can present as solitary lesions or be a component of systemic illnesses like tuberous sclerosis, which features shagreen's patches, another form of collagenoma, as an associated feature, or Buschke–Ollendorff syndrome, which is linked to collagenomas and elastomas.
=== Length === Most classical cannabinoids are 21-carbon compounds, but variations in the side-chain length attached to the aromatic ring exist. In THC, CBD, and CBN, the side-chain is a pentyl (5-carbon) chain. Propyl (3-carbon) chain variants are named with the suffix varin (THCV, CBDV, CBNV), while heptyl (7-carbon) chain variants are named phorol (THCP, CBDP).
While many languages and dialects are spoken in the United States, English is by far the most commonly spoken and written. English was designated the official language of the United States by Executive Order 14224 in March 2025. However, the U.S. has never had a statutory official language, as Congress has never passed a law to designate English as official for all three federal branches. Some laws, such as U.S. naturalization requirements, nonetheless standardize English. Twenty-eight states and the United States Virgin Islands have laws that designate English as the sole official language; 19 states and the District of Columbia have no official language. Three states and four U.S. territories have recognized local or indigenous languages in addition to English: Hawaii (Hawaiian), Alaska (twenty Native languages), South Dakota (Sioux), American Samoa (Samoan), Puerto Rico (Spanish), Guam (Chamorro), and the Northern Mariana Islands (Carolinian and Chamorro). In total, 169 Native American languages are spoken in the United States. In Puerto Rico, Spanish is more widely spoken than English. According to the American Community Survey (2020), some 245.4 million people in the U.S. age five and older spoke only English at home. About 41.2 million spoke Spanish at home, making it the second most commonly used language. Other languages spoken at home by one million people or more include Chinese (3.40 million), Tagalog (1.71 million), Vietnamese (1.52 million), Arabic (1.39 million), French (1.18 million), Korean (1.07 million), and Russian (1.04 million).
Sources: en.wikipedia.org
On 1 May 1989, the American Physical Society held a session on cold fusion in Baltimore, including many reports of experiments that failed to produce evidence of cold fusion. At the end of the session, eight of the nine leading speakers stated that they considered the initial Fleischmann and Pons claim dead, with the ninth, Johann Rafelski, abstaining. Steven E. Koonin of Caltech called the Utah report a result of "the incompetence and delusion of Pons and Fleischmann," which was met with a standing ovation. Douglas R. O. Morrison, a physicist representing CERN, was the first to call the episode an example of pathological science. On 4 May, due to all this new criticism, the meetings with various representatives from Washington were cancelled. From 8 May, only the A&M tritium results kept cold fusion afloat. In July and November 1989, Nature published papers critical of cold fusion claims. Negative results were also published in several other scientific journals including Science, Physical Review Letters, and Physical Review C (nuclear physics). In August 1989, in spite of this trend, the state of Utah invested $4.5 million to create the National Cold Fusion Institute. The United States Department of Energy organized a special panel to review cold fusion theory and research. The panel issued its report in November 1989, concluding that results as of that date did not present convincing evidence that useful sources of energy would result from the phenomena attributed to cold fusion.
As of 2018, there are around 470 million pet dogs. Pet food production is responsible for 20–30% of the environmental impacts from animal production. It has been estimated that global greenhouse gas emissions from dog and cat dry food represents around 1.1%−2.9% of global emissions, an amount close to the total emissions of countries such as Mozambique or the Philippines. Like humans, dogs are omnivores. There is research on alternative protein sources for pet food including insects and algae. A life-cycle analysis of contemporary pet foods suggests wet foods for cats and dogs tend to have a larger impact than dry foods. It also suggests there are substantial opportunities for improvement in "all phases of the pet food life cycle, including formulation, ingredient selection, manufacturing processes" and so on.
The 9th Marine Infantry Brigade (French: 9e Brigade d'Infanterie de Marine, 9e BIMa) is a light armoured, amphibious unit of the Troupes de marine of the French Army. In July 1963, the 9e Brigade was created in Brittany. On 1 January 1976, the 9th Brigade became the 9th Marine Infantry Division (9e division d'Infanterie de Marine, 9e DIMa), attached to the land intervention force, then the Rapid Action Force from 1984. On 1 July 1999, the 9th Marine Infantry Division became the 9th Marine Light Armoured Brigade. On 1 January 2013, the unit was renamed to the 9th Marine Infantry Brigade (French: 9e Brigade d'Infanterie de Marine, 9e BIMa).
Sources: en.wikipedia.org
=== Protein === Additional research on sponge proteins found that of 42 sponge proteins that were analysed, all of them had homologous proteins that are found in humans. An identity score of 53% was given to the similarity among sponge and human proteins, compared to a score of 42% when the same sequence was compared to that of C. elegans.
The treatment of choice for this condition is the surgical application of epidural blood patches, which has a higher success rate than conservative treatments of bed rest and hydration. Through the injection of a person's own blood into the area of the hole in the dura, an epidural blood patch uses blood's clotting factors to clot the sites of holes. The volume of autologous blood and number of patch attempts for patients is highly variable. One-quarter to one-third of those with a sCSFL patients do not have relief of symptoms from epidural blood patching. Finding the location of a cerebrospinal fluid leak is not required prior to using an epidural blood patch as initial lumbar epidural blood patches often provide relief of symptoms and resolve the leak without further intervention.
== Production == On 14 October 2025, it was announced via the shows official Instagram page, that casting for the fourth season was now open. Applications remained open for four weeks until closing on 6 November 2025. Ten contestants were announced on 24 April 2024. Participants include Malawitte, the Drag Race franchise's fifth cisgender female contestant. On the same day it was announced that Nicky Doll and Daphné Bürki would recur in their roles again during the season, while Loïc Prigent (who was already on the judging panel during the All Stars installment) and Anggun are joining the judging panel to take the place of Kiddy Smile.
=== 2015 === The index crossed the historical mark of 30,000 after repo rate cut announcement by RBI. The index plummeted by over 1,624.51 points on 24 August 2015, the then worst one-day point plunge in the index's history.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.